Thermo Fisher Scientific Inc Stock (TMO) Moved Down by 3.31% on Mar 27: What Investors Need To Know

Thermo Fisher Scientific Inc (TMO) moved down by 3.31%. The Healthcare Services & Equipment sector is down by 2.35%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Unitedhealth Group Inc (UNH) down 4.21%; Abbott Laboratories (ABT) down 0.31%; Boston Scientific Corp (BSX) down 0.84%.

What is driving Thermo Fisher Scientific Inc (TMO)’s stock price down today?

Thermo Fisher Scientific's stock experienced a downward movement today, likely influenced by a confluence of factors including broader market sentiment, concerns over profitability, and ongoing integration considerations following a significant acquisition. While the company has consistently surpassed earnings estimates in recent quarters, its shares traded lower after its fourth-quarter results, driven by investor focus on margin pressures and a cautious outlook for its 2026 adjusted earnings per share guidance, which came in below prior analyst expectations at the midpoint. The firm has also seen a decline in adjusted EBIT and gross margins over recent years, reflecting challenges in maintaining operational efficiency and profitability.

The general market environment also appears to be a contributing factor. The overall market experienced significant selling pressure in the preceding trading session, with major indices closing considerably lower due to worries about rising inflation and potential adjustments to monetary policy. A broad market downturn often impacts individual stock performance, even for companies with generally positive long-term outlooks.

Moreover, Thermo Fisher Scientific recently completed its acquisition of Clario Holdings for a substantial cash sum earlier this week. While this acquisition is strategically important and anticipated to contribute to adjusted earnings per share in the first year, it introduces risks associated with integration challenges, potential disruptions to business operations, and the successful realization of expected synergies. Such large-scale mergers often lead to short-term market uncertainty. Additionally, recent insider sales by company executives and an institutional adjustment by Vanguard, which amended its 13G filing to report no shares, could be perceived negatively by the market, signaling a shift in sentiment or portfolio positioning.

Despite these pressures, analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and several firms initiating or reiterating "buy" ratings with notable price targets. However, the stock has underperformed broader market indices over the past year. The combination of macroeconomic headwinds, lingering profitability concerns from recent guidance, risks tied to a large acquisition, and some insider and institutional selling activity appear to be weighing on the stock's performance today.

Technical Analysis of Thermo Fisher Scientific Inc (TMO)

Technically, Thermo Fisher Scientific Inc (TMO) shows a MACD (12,26,9) value of [-17.14], indicating a neutral signal. The RSI at 43.64 suggests neutral condition and the Williams %R at -41.62 suggests oversold condition. Please monitor closely.

Fundamental Analysis of Thermo Fisher Scientific Inc (TMO)

Thermo Fisher Scientific Inc (TMO) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $44.56B, ranking 2 in the industry. The net profit is $6.70B, ranking 1 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $661.07, a high of $750.00, and a low of $595.00.

More details about Thermo Fisher Scientific Inc (TMO)

Company Specific Risks:

• The recently completed $8.875 billion acquisition of Clario Holdings, Inc. introduces significant integration challenges, including potential operational disruptions, difficulties in retaining key personnel, and risks in fully realizing anticipated synergies and operating efficiencies.
• The integration of Clario Holdings into Thermo Fisher's existing PPD segment may lead to a loss of perceived neutrality for Clario, potentially causing attrition among external Contract Research Organizations (CROs) and biopharma clients who might be reluctant to share sensitive trial data with a competitor's subsidiary.
• Analysts have noted a significant decline in adjusted EBIT margin (approximately 830 basis points from 2021 to 2024) and adjusted gross margin (roughly 940 basis points lower than 2019 levels), indicating a deterioration in operational efficiency and challenges in maintaining profitability.
• Thermo Fisher faces headwinds from a substantial slowdown in biotech sector research and development funding, evidenced by a 45% year-over-year decline in capital raised during the first half of 2025, which could negatively impact future revenue growth prospects for its life science solutions segment.